GlassScriptPhysician profile
Denise Barnard
NPI 1366511206
$4,943.61
in general payments reported to CMS, 2019-2025
23 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $227 · 2021: $727 · 2022: $1,048 · 2023: $584 · 2024: $521 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.03 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $550.71 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $509.09 | 2019-2024 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.45 | 2021-2025 | Caplyta |
| Tris Pharma INC | $319.43 | 2019-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Janssen Pharmaceuticals, INC | $263.48 | 2019-2024 | Spravato |
| Allergan, INC. | $215.34 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $193.57 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $189.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.24 | 2019-2022 | |
| Alkermes, INC. | $163.84 | 2021-2023 | Lybalvi |
| Jazz Pharmaceuticals INC. | $146.53 | 2019-2021 | |
| Neos Therapeutics, LP | $95.60 | 2019-2022 | |
| Corium, LLC | $89.68 | 2022 | |
| Lundbeck LLC | $81.45 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $70.29 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $36.45 | 2019 | |
| Shire North American Group INC | $31.41 | 2019 | |
| Adlon Therapeutics L.P. | $19.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.22 | 2022 | |
| Neurocrine Biosciences, INC. | $17.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.28 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.